Confirmed speakers

Vassili Soumelis, MD, PhD

His team combines expertise in immunology, computational biology, and medicine. Vassili Soumelis coordinated a European FP6 Excellence Grant (2005-2009), participated in a EuroTransbio project (2007-2009), coordinated bioinformatics and systems biology in the European consortium MAARS (FP7), and received ERC consolidator and proof-of-concept grants.

He is currently the coordinator of the H2020 project ImmunAID, working on multi-omics data integration for the diagnostic classification of rare auto-inflammatory diseases.
V. Soumelis has published over 80 scientific articles in international journals. He is serving as a reviewer for many research journals, including Nature, Immunity, Nature Communications, the Journal of Experimental Medicine, Plos Computational Biology.

Confirmed speakers so far:

Confirmed speaker
Alan Melcher, MD, PhD

Professor Alan Melcher graduated in medicine from the University of Oxford in 1989, and trained in Clinical Oncology (Radiotherapy and Chemotherapy) in Cardiff, London and Leeds.

Confirmed speaker
Caroline Robert, MD, PhD

Caroline Robert, M.D., Ph.D., is the Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University.

Confirmed speaker
Eric Vivier, DVM, PhD

Eric Vivier, DVM, PhD, is a professor of immunology at Aix-Marseille University, France. He graduated with the highest honors (silver medal) from the Ecole Nationale Vétérinaire de Maisons-Alfort and received his doctoral degree in immunology from Paris XI University.

organizer
Eric Deutsch MD, PhD

Eric Deutsch, MD, PhD, full-Professor in Radiation Oncology at South-Paris University, head of the Inserm Unit 1030 « Molecular Radiology Laboratory » and Head of the Radiation Oncology Department in Villejuif, France.

Organizer
Silvia C. Formenti, MD

During the past twelve years, Dr. Formenti has introduced a paradigm shift in radiation biology, by elucidating the role of ionizing radiation on the immune system, and demonstrating efficacy of combining radiotherapy with immunotherapy in solid tumors.

Confirmed speaker
Guido Kroemer, MD, PhD

His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise. His contributions have been recognized with numerous awards, including the prestigious Descartes Prize of the European Union, the Carus Medal of the German Academy of Sciences, the Grand Prix Mergier-Bourdeix of the French Academy of Sciences, the Lucien Dautrebande Prize of the Belgian Royal Academy of Medicine, the Gallet & Breton Prize of the French Academy of Medicine and others.

Organizer
Sandra Demaria, MD

Dr. Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. She was the first to show that radiotherapy can convert tumors unresponsive to immune checkpoint inhibitors into responsive ones, a finding being translated in several clinical trials at multiple institutions.

Confirmed speaker
Florent Ginhoux, PhD

As a postdoctoral fellow, Florent Ginhoux joined the Laboratory of Miriam Merad in the Mount Sinai School of Medicine (MSSM), New York where he studied the ontogeny and the homeostasis of cutaneous dendritic cell populations, with a strong focus on Langerhans cells.

Confirmed speaker
Laurence Zitvogel, MD, PhD

During the lecture, Prof. Zitvogel will discuss the association between the gut microbiota and therapeutic effectiveness of alkylating agents, platinum salts, and immune checkpoint inhibitors. Additionally, Prof. Zitvogel will cover the latest findings that support the diagnosis of dysbiosis in patients with cancer and the predictive gut biomarkers of sensitivity or resistance to PD-1 blockade.

Confirmed speaker
Lorenzo Galluzzi, PhD

Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Comprehensive Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2005-2008).

Confirmed speaker
Jérôme Galon, MD, PhD

Dr. Galon was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France). He holds a Ph.D. degree in Immunology (Jussieu University, Paris, France, 1996). Between 1997 and 2001 he worked at the NIH (National Institute of Health, Bethesda, USA) on functional genomics, bioinformatics and immunology on fundamental and clinical research.

Confirmed speaker
Ignacio Melero, MD, PhD

In 1994 he moved to Seattle, WA where he worked on tumor immunology and immunotherapy, studying T cell ignorance of tumor antigens and the role of T cell costimulation in mouse models of cancer. His studies of that time on CD137-mediated co-stimulation of curative antitumor immune responses have received much attention by the immunotherapy of cancer community and have resulted in therapeutic agents undergoing phase II clinical trials.

Confirmed speaker
Udo Gaipl, MD, PhD

Since 2007 he heads the Radiation Immunobiology and is head of the Experimental Radiation Oncology of the German Society for Radiation Oncology (DEGRO). Since 2015 he his Professor for Experimental Medicine and has published more than 160 peer-reviewed papers on immune modulations by radiation and stressed cells.

Confirmed speaker
Vassili Soumelis, MD, PhD

His team combines expertise in immunology, computational biology, and medicine. Vassili Soumelis coordinated a European FP6 Excellence Grant (2005-2009), participated in a EuroTransbio project (2007-2009), coordinated bioinformatics and systems biology in the European consortium MAARS (FP7), and received ERC consolidator and proof-of-concept grants.

Confirmed speaker
Jean-Luc Perfettini, PhD

Jean-Luc PERFETTINI is currently developing an integrative research program in the field of radiation oncology that aims at characterizing ionizing radiations-induced cell death and senescence modalities, developing preclinical mouse models to study the immune responses elicited by anti-cancer treatments, and identifying innovative therapeutic approaches that could improve the effectiveness of anticancer treatments.

Confirmed speaker
Michele Mondini, PhD

Scientific and managing executive of an early stage biotech start-up. Lecturer in Clinical Diagnostic. Mentoring of students. Specialties: Research in the field of radiotherapy, immunotherapy and virology.

Confirmed speaker
Patrick Roth, MD

He has managed the Neurosurgery Residency Program at HUMC for nearly twenty years, served as a perennial teacher of third year medical students, and regularly mentors high school and college students interested in a career in medicine. He is currently attending the Mailman School of Public Health at Columbia University where he will obtain a Masters in Healthcare Administration.

Confirmed speaker
Ruth J. Muschel, MD, PhD

She continued on staff at the NCI before taking an academic position at the University of Pennsylvania, where she advanced to the rank of Professor.

Confirmed speaker
Sergey Nikolaev, PhD

He worked as a postdoctorate researcher at the King’s College in London (UK), at SPINTEC in Grenoble (France), and at the National Institute for Materials Science in Tsukuba (Japan).

previous arrow
next arrow
Slider

cookiesWe care about your data, and we'd
love to use cookies to make your
experience better. Cookie Policy